Global Gastroparesis Drugs Market Size study, by Drug Class (Prokinetic Agents, Antiemetic Agents, Botulinum Toxin Injections), Disease Type, End-use and Regional Forecasts 2022-2032

Global Gastroparesis Drugs Market is valued approximately at USD 4.6 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.60% over the forecast period 2024-2032. Gastroparesis, characterized by delayed gastric emptying without mechanical obstruction, poses a multifaceted treatment challenge due to its complex etiology. The growing prevalence of diabetes mellitus, particularly Type 1 and Type 2, is a key contributor to rising gastroparesis diagnoses globally. As a result, demand for pharmacological interventions has surged, paving the way for a competitive and innovation-driven gastroparesis drugs market. Emerging therapeutics are targeting not just symptomatic relief, but also the underlying pathophysiology, offering healthcare providers more options for tailoring treatments to patient profiles.

The market has seen considerable traction around prokinetic agents, which enhance gastric motility and offer foundational management for gastroparesis. However, as treatment-resistant cases rise, attention has shifted toward newer formulations of antiemetics and botulinum toxin injections, which offer relief for nausea, vomiting, and abdominal discomfort. Pharmaceutical companies are reconfiguring existing drug molecules for enhanced gastrointestinal selectivity, while also exploring novel mechanisms of action to mitigate side effects and improve patient adherence. Regulatory bodies such as the FDA and EMA have been expediting approvals for orphan-designated drugs in gastroparesis, further spurring clinical trial investments.

Despite this momentum, the market faces certain friction points. The variable efficacy of existing therapies, high cost of advanced treatments, and the absence of curative options are significant concerns. Moreover, gastroparesis often presents as a secondary condition, making early diagnosis elusive and complicating therapeutic response tracking. Nevertheless, the integration of digital symptom tracking tools, real-world evidence-based data, and gastroenterology-focused telemedicine consultations is expected to refine clinical pathways and foster earlier intervention, indirectly propelling drug demand.

Pharmaceutical companies are actively forming partnerships with academic institutions and biotechnology startups to co-develop promising drug candidates. Meanwhile, distribution strategies are evolving with increased penetration through hospital pharmacies and specialty clinics. As awareness of functional gastrointestinal disorders grows, so too does the influence of patient advocacy groups, who are demanding better access, insurance coverage, and treatment transparency. This shift is encouraging pharma firms to enhance patient-centric strategies and expand post-launch support programs, especially in chronic cases requiring long-term care.

Regionally, North America commands the largest share of the gastroparesis drugs market due to robust healthcare reimbursement systems, high diabetes prevalence, and a well-established network of gastroenterologists. Europe follows closely, particularly driven by countries like Germany, France, and the UK, where clinical research in motility disorders is well funded. Asia Pacific is expected to register the highest CAGR over the forecast period, catalyzed by improving diagnostic infrastructure, increasing patient pool, and expanding pharmaceutical sales networks in countries like India, China, and Japan. Meanwhile, Latin America and the Middle East & Africa present untapped potential as global manufacturers turn their focus to broader market penetration and localization strategies.

Major market player included in this report are:
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Abbott Laboratories
• Teva Pharmaceutical Industries Ltd.
• Evoke Pharma, Inc.
• Salix Pharmaceuticals, Ltd.
• Medtronic plc
• Johnson & Johnson Services, Inc.
• Mylan N.V.
• Theravance Biopharma
• AstraZeneca plc
• Cadila Healthcare Limited (Zydus)
• ANI Pharmaceuticals, Inc.
• Cipla Ltd.
• Neurogastrx, Inc.

The detailed segments and sub-segment of the market are explained below:

By Drug Class
• Prokinetic Agents
• Antiemetic Agents
• Botulinum Toxin Injections

By Disease Type
• Diabetic Gastroparesis
• Idiopathic Gastroparesis
• Post-surgical Gastroparesis
• Others

By End-use
• Hospitals
• Clinics
• Homecare
• Others

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical year: 2022
• Base year: 2023
• Forecast period: 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.